Dynavax Technologies Co. (NASDAQ:DVAX) insider David F. Novack sold 16,109 shares of the company’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $16.30, for a total transaction of $262,576.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
DVAX opened at $18.55 on Monday. The company has a market cap of $1,144.18, a P/E ratio of -10.72 and a beta of 0.84. Dynavax Technologies Co. has a 1 year low of $5.05 and a 1 year high of $24.45.
Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.32). Dynavax Technologies had a negative return on equity of 57.43% and a negative net margin of 29,099.08%. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.53 million. analysts expect that Dynavax Technologies Co. will post -1.91 earnings per share for the current year.
Large investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. grew its position in Dynavax Technologies by 29.9% in the third quarter. Schwab Charles Investment Management Inc. now owns 235,310 shares of the biopharmaceutical company’s stock valued at $5,060,000 after acquiring an additional 54,149 shares in the last quarter. Swiss National Bank grew its position in Dynavax Technologies by 40.7% in the third quarter. Swiss National Bank now owns 99,878 shares of the biopharmaceutical company’s stock valued at $2,147,000 after acquiring an additional 28,900 shares in the last quarter. First Republic Investment Management Inc. acquired a new stake in Dynavax Technologies in the third quarter valued at approximately $2,414,000. Bank of New York Mellon Corp grew its position in Dynavax Technologies by 43.4% in the third quarter. Bank of New York Mellon Corp now owns 359,650 shares of the biopharmaceutical company’s stock valued at $7,733,000 after acquiring an additional 108,788 shares in the last quarter. Finally, Northern Trust Corp grew its position in Dynavax Technologies by 20.7% in the second quarter. Northern Trust Corp now owns 571,883 shares of the biopharmaceutical company’s stock valued at $5,519,000 after acquiring an additional 98,251 shares in the last quarter. 71.22% of the stock is owned by institutional investors.
DVAX has been the subject of a number of research analyst reports. BidaskClub raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, March 27th. Royal Bank of Canada reaffirmed a “buy” rating and set a $25.00 price objective on shares of Dynavax Technologies in a research note on Friday, March 9th. Cowen reaffirmed a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research note on Wednesday, February 21st. ValuEngine raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, March 27th. Finally, JPMorgan Chase downgraded shares of Dynavax Technologies from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $31.00 to $25.00 in a research report on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $24.67.
WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/04/09/dynavax-technologies-co-dvax-insider-david-f-novack-sells-16109-shares.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.